No benefits seen with application of platelet- and leucocyte-rich fibrin during rotator cuff repair
Click Here to Manage Email Alerts
Results from this level 1 study showed clinical outcomes, anatomic healing rate, and mean postoperative defect size and tendon quality at 1 year did not improve with the application of leucocyte- and platelet-rich fibrin during arthroscopic rotator cuff repair.
Researchers assessed 35 consecutive patients with a mean age of 65.3 years who underwent primary arthroscopic repair for posterosuperior full-thickness rotator cuff tears. Through block randomization, 18 patients were randomly selected to the test group and underwent arthroscopy with leucocyte- and platelet-rich plasma fibrin and 17 patients underwent arthroscopy without platelet-rich concentrates. Investigators assessed patients with the VAS pain score, subjective shoulder value (SSV), simple shoulder test (SST) and the Constant and Murley score. At the 12-month follow-up, patients were evaluated with MRI arthrography for anatomic watertight healing, tendon quality and tendon thickness. The mean follow-up was 14 months.
Results showed there were no intraoperative and postoperative complications or need for revision surgery. Both SSV and SST scores improved significantly from preoperative to postoperative measures in both groups.
Eleven patients in both groups had anatomic watertight healing. The platelet-rich concentrate group had a mean postoperative defect size of 214 mm², and the comparison group had a mean defect size of 161 mm². Mean postoperative tendon quality as measured by Sugaya grade was not significantly different between the groups at 12 months. ‒ by Monica Jaramillo
Disclosures: The study was funded by the European Society for Surgery of the Shoulder and Elbow with the Societe Europeenne pour la Chirurgie de l’Epaule et du Coude (SECES) Research Grant 2008. Additional support was received from the Swiss Society of Orthopedic Surgery and Traumatology.